Latest Conference Articles

November 6th 2014, 12:25pm

PER® Chemotherapy Foundation Symposium (CFS)

In May 2014, ASCO issued guidelines recommending the administration of adjuvant tamoxifen for 10 years in women with stage I-III hormone receptor (HR)-positive breast cancer, based on data from the collection of 5 clinical trials.

November 5th 2014, 2:06pm

PER® Chemotherapy Foundation Symposium (CFS)

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses lymphocytosis following treatment with a B-cell receptor inhibitor.

November 5th 2014, 1:03pm

PER® Chemotherapy Foundation Symposium (CFS)

When Gail J. Roboz, MD, took the stage Wednesday to give her talk on what's ahead in the treatment of acute myeloid leukemia (AML), she admitted feeling a little jealousy toward her colleagues in the lymphoid diseases.

November 5th 2014, 12:52pm

PER® Chemotherapy Foundation Symposium (CFS)

The landscape in lymphoma management continues to evolve, with new therapies and approaches improving established treatment paradigms

November 5th 2014, 12:28pm

PER® Chemotherapy Foundation Symposium (CFS)

As the targeted therapy era in chronic lymphocytic leukemia (CLL) continues to unfold, two next-generation agents are generating responses with improved safety profiles as single agents and in combination regimens

November 5th 2014, 11:28am

PER® Chemotherapy Foundation Symposium (CFS)

The combination of a FLT3L-primed in situ vaccine, low-dose radiotherapy, and a toll-like receptor 3 (TLR) 3 agonist has been shown to be feasible, safe, and immunologically and clinically effective in a phase I/II study for patients with low-grade lymphoma

November 2nd 2014, 12:20pm

Annual Meeting of the American Thyroid Association

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses the rapidly changing treatment landscape for patients with differentiated thyroid cancer.

November 2nd 2014, 12:05pm

Annual Meeting of the American Thyroid Association

Julie A. Sosa, MD, MS, professor of surgery and medicine, chief of endocrine surgery, Duke University, discusses molecular testing for thyroid cancer.

November 2nd 2014, 10:05am

Annual Meeting of the American Thyroid Association

A next-generation sequencing assay has shown promise as a new tool to aid in the diagnosis and treatment of indeterminate thyroid nodules.

November 2nd 2014, 9:39am

Annual Meeting of the American Thyroid Association

The ThyroSeq v2 next-generation sequencing assay was highly accurate at diagnosing cancer in thyroid nodules with follicular neoplasm or those suspected of follicular neoplasm cytology.

November 1st 2014, 4:03pm

Annual Meeting of the American Thyroid Association

Preoperative vitamin D deficiency is associated with postoperative symptomatic hypocalcemia in patients with thyroid cancer undergoing total thyroidectomy plus central compartment neck dissection.

November 1st 2014, 3:39pm

Chicago Multidisciplinary Symposium in Thoracic Oncology

Roy S. Herbst, MD, PhD, presented a top 10 list on immunotherapy in non-small cell lung cancer at the 2014 Multidisciplinary Symposium in Thoracic Oncology.

November 1st 2014, 12:51pm

Annual Meeting of the American Thyroid Association

In vivo models for two aggressive thyroid cancers have shown that downregulation of miR-30a-5p leads to overexpression of LOX, a target which appears amenable to treatment with β-aminopropionitrile fumarate.

November 1st 2014, 12:25pm

Annual Meeting of the American Thyroid Association

The detection of BRAFV600E in patients with papillary thyroid cancer using a blood-based assay was shown to be feasible in a cohort of patients undergoing thyroidectomy.

November 1st 2014, 11:08am

Annual Meeting of the American Thyroid Association

Ian Ganly, MD, PhD, from Memorial Sloan Kettering Cancer Center, discusses the development of a postoperative nomogram for predicting cancer-specific mortality in MTC.

November 1st 2014, 8:10am

Chicago Multidisciplinary Symposium in Thoracic Oncology

Jyoti D. Patel, MD, thoracic oncologist, Northwestern University Feinberg School of Medicine, discusses the benefits of multidisciplinary approach for the treatment of patients with stage III disease.

November 1st 2014, 7:59am

Chicago Multidisciplinary Symposium in Thoracic Oncology

David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses results from a phase III study exploring eribulin for the treatment of patients with non-small cell lung cancer.

November 1st 2014, 7:52am

Chicago Multidisciplinary Symposium in Thoracic Oncology

Nivolumab combined with platinum-based doublet chemotherapy achieved a manageable safety profile with clinical efficacy that was similar to single-agent nivolumab in patients with advanced NSCLC.

November 1st 2014, 7:31am

Chicago Multidisciplinary Symposium in Thoracic Oncology

Jyoti D. Patel, MD, provides insight into managing the toxicities associated with molecular therapies used to treat patients with lung cancers.

November 1st 2014, 7:15am

Annual Meeting of the American Thyroid Association

Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the promise of pemetrexed and carboplatin as a potential treatment option for patients with follicular cell-derived thyroid cancers.